ClinicaliQ Trial Snapshot
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician’s Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — Active Not Recruiting • Phase III • Oncology • NCT04961996.
- Giredestrant versus standard hormone therapy for early breast cancer: a Phase III trial testing a new treatment option.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of endocrine therapy in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. Conditions: Early Breast Cancer Interventions: Giredestrant, Physician's Choice of Endocrine Therapy, LHRH Agonist Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 4170 participants